Takeda Signs Up to $1.7B Deal to Use Iambic’s AI Technology for Drug Discovery
Takeda Signs Up to $1.7B Deal to Use Iambic’s AI Technology for Drug Discovery
Publish Date: 2026-02-09 14:00:00
Source Domain: www.pymnts.com
Takeda Pharmaceutical is deepening its push into artificial intelligence–enabled drug research, striking a multiyear agreement with Iambic Therapeutics that could be worth as much as $1.7 billion in milestone payments.
The Tokyo-based drugmaker will gain access to Iambic’s suite of AI-driven discovery technologies, including its generative modeling system NeuralPLexer, as it looks to advance small molecule programs across oncology, gastrointestinal and inflammation indications. The agreement includes upfront payments covering research costs and technology access, though the companies did not disclose specific figures. Milestone payments tied to development and commercialization achievements could push the total value of the collaboration past $1.7 billion, according to Fierce BioTech, citing a Feb. 9 press release.
The size of the potential payout places the arrangement among the largest artificial intelligence–focused drug discovery partnerships to date, per Fierce BioTech, underscoring the pharmaceutical industry’s increasing appetite for AI-enabled research platforms.
Iambic CEO Tom Miller sought to distinguish his company from what he characterized as hype surrounding artificial intelligence in biotech. “As you think about the AI space, work your way through landscape, and categorize Iambic as company, it is not about AI hype,” Miller told Fierce Biotech. “We are showing in patients that these drugs are better, creating validation.”
Under the terms of the deal, Takeda will deploy Iambic’s software tools and drug discovery capabilities to help identify and optimize new therapeutic candidates. NeuralPLexer, one of the centerpiece technologies included in the agreement, is designed to model protein–ligand interactions, a key step in predicting how potential drugs bind to their biological targets.
In a statement announcing the partnership, Miller said, “Our collaboration with Takeda is a powerful opportunity to apply our AI-driven…
.jpg "EBU unveils nominees for Technology and Innovation Awards 2026")
